Login to Your Account



Synribo Clears FDA Hurdle, Gains Nod in CML Patients

By Jennifer Boggs
Managing Editor

Monday, October 29, 2012
Three years after a new drug application was first submitted for leukemia drug omacetaxine mepesuccinate, during which the product moved twice into different hands via M&A transactions, the FDA granted a long-awaited nod Friday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription